AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year. https://t.co/b5hOwTxWaU https://t.co/Wq5EsZGLK5
@Reuters
AstraZeneca to buy EsoBiotec in $1 billion deal to advance cell therapy ambition
SeekingAlpha
FibroGen sells China unit to AstraZeneca for $160 million
SeekingAlpha
AstraZeneca's Enhertu breast cancer drug added to China's state insurance list https://t.co/ANXcJ37J86 https://t.co/a5p6npwgWs
@Reuters
Healthy Returns: AstraZeneca expands U.S. investment plan on confidence in economy
CNBC
AstraZeneca $AZN Q3 2024 earnings were released today before the market opened:
- Revenue: $13.56B vs $13.09B
- EPS: $1.04 vs $1.03 https://t.co/L9YMcRERaB
@Benzinga
AstraZeneca says detained China head has lawyer, but company still in dark https://t.co/e0JZ5gcq4d https://t.co/lqYDxOEImo
@Reuters
AstraZeneca sheds £15 billion of market cap as weight-loss-pill data underwhelms investors
MarketWatch
AstraZeneca to pay up to $2 billion to license cardiovascular drug
MarketWatch
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line https://t.co/xnIivIV4Db https://t.co/myFZAy8W5A
@Reuters
US FDA approves AstraZeneca's non-small cell lung cancer treatment https://t.co/mkQJ7SUj5c https://t.co/d9xgiaNCJh
@Reuters
Why CEO AstraZeneca believes the pharmaceutical company can almost double revenues by 2030
CNBC
AstraZeneca completes acquisition of Fusion Pharmaceuticals
SeekingAlpha
Ontario court approves AstraZeneca/Fusion acquisition plan
SeekingAlpha
Fusion shareholders give green light to AstraZeneca acquisition
SeekingAlpha
AstraZeneca to build $1.5 billion cancer drug manufacturing plant in Singapore - Reuters
Reuters
Pfizer wins $107.5 million from AstraZeneca in US cancer drug patent trial https://t.co/1HCc8JsuZy https://t.co/bHfQ2WNCOK
@Reuters
AstraZeneca to increase 2024 dividend by 7% on strong growth https://t.co/EwtVdAukKA https://t.co/0HTPRgW6KL
@Reuters
AstraZeneca will buy Fusion Pharmaceuticals for ~$2B
SeekingAlpha
AstraZeneca to expand rare disease pipeline with $1.05B Amolyt Pharma acquisition
SeekingAlpha
Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca
SeekingAlpha
U.S. FDA approves AstraZeneca's Tagrisso-chemo combo https://t.co/KFPYOpWTGR https://t.co/RPuUvz1XQ1
@Reuters
Icosavax ticks lower as HSR filing for AstraZeneca deal withdrawn, refiled
SeekingAlpha
Sell AstraZeneca, says UBS, which upgrades European rivals including GSK
MarketWatch
AstraZeneca to buy Gracell Biotechnologies for $1.2 billion
SeekingAlpha
Ionis Pharmaceuticals, AstraZeneca get FDA approval for rare genetic disease treatment
MarketWatch
Cytokinetics gains amid report of Novartis, AstraZeneca takeover interest
SeekingAlpha
AstraZeneca to acquire vaccine maker Icosavax in ~$1.1B deal
SeekingAlpha
Icosavax enters agreement to be acquired by Astrazeneca
SeekingAlpha
AstraZeneca partners with AI company to find cure for cancer
CoinTelegraph
AstraZeneca and Absci Collaborate on AI-Driven Cancer Therapy Development
Cryptopolitan
Drug Giant AstraZeneca Launches Evinova to Quicken Clinical Trials
Decrypt
CDC expedites release of more doses of infant RSV drug from Sanofi, AstraZeneca amid shortage
CNBC
AstraZeneca prioritizes US for RSV drug amid surge in cases https://t.co/2KxUhShyqN https://t.co/mxvzb9oZ2C
@Reuters
AstraZeneca adds player to obesity drug race, but Eli Lilly remains in the lead
CNBC
AstraZeneca hikes earnings forecast as surging cancer drug sales offset plunging revenue from COVID vaccines
MarketWatch
AstraZeneca ups profit outlook on strong cancer drugs demand https://t.co/SJ29rHCteS https://t.co/wVyx5Ey8J0
@Reuters
Nanoform Grants AstraZeneca Global STARMAP AI License for Innovative Nanoparticle Medicine Development
Cryptopolitan
As Merck, AstraZeneca and other drugmakers sign on, Medicare price negotiations face critical moment
MarketWatch
AstraZeneca, Boehringer Ingelheim to participate in Medicare drug price negotiations
CNBC
Stocks making the biggest moves in premarket trading: AstraZeneca, Paramount, Nike and more
CNBC
Stocks making the biggest moves premarket: AstraZeneca, Wayfair, Alibaba and more
CNBC
AstraZeneca strikes $1 billion deal for Pfizer rare-disease gene therapies
MarketWatch
AstraZeneca to buy Pfizer's rare disease gene therapy portfolio for up to $1 bln https://t.co/I8WZPzelun https://t.co/xgZG4kGfem
@Reuters
AstraZeneca shares slump after Phase 3 lung cancer drug study
MarketWatch
Movers & Shakers: Tesla shares rally on delivery numbers, AstraZeneca stock slumps on drug trial, and other stocks on the move
MarketWatch
AstraZeneca to decarbonize U.S. footprint by turning cow manure into renewable natural gas
MarketWatch
FDA advisors recommend AstraZeneca antibody to protect babies from RSV
CNBC
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients https://t.co/CkP8azLYR3 https://t.co/aeTHroPnGX
@Reuters
AstraZeneca's Tagrisso slashes death risk in certain post-surgery lung cancer patients - Reuters
Reuters
FAQ
Berapa harga saham AstraZeneca PLC hari ini?
Harga saat ini dari AstraZeneca PLC adalah 142.50 USD — harga tersebut telah meningkat sebesar 0.71% dalam 24 jam terakhir. Pantau kinerja harga saham AstraZeneca PLC lebih dekat di grafik lanjutan.
Apa simbol saham AstraZeneca PLC?
Tergantung pada bursa, simbol saham bisa berbeda. Misalnya, di bursa PINK, saham AstraZeneca PLC diperdagangkan dengan simbol AZNCF.
Apakah harga saham AZNCF naik?
Saham AZNCF telah menurun sebesar 0.00% dalam seminggu terakhir, telah menurun sebesar -2.89% dalam sebulan terakhir, dan telah menurun sebesar -7.34% dalam setahun terakhir. Lihat lebih banyak data di grafik AZNCF.
Apa rekomendasi analis untuk AZNCF?
Hingga 03 giu 2025, dari 49 rekomendasi analis, mayoritas memberikan rating AZNCF sebagai buy.
Apa kapitalisasi pasar AZNCF?
Hingga hari ini, AZNCF memiliki kapitalisasi pasar sebesar 219.35B USD. Jelajahi daftar saham kami yang diperingkat berdasarkan kapitalisasi pasar untuk membandingkan AZNCF dengan saham lainnya.
Apakah AZNCF merilis laporan keuangan?
Ya, Anda dapat melacak keuangan AZNCF dalam laporan tahunan dan kuartalan di Profit.com.
Kapan tanggal laporan pendapatan AZNCF berikutnya?
AZNCF akan merilis laporan pendapatan berikutnya pada 29 lug 2025. Pantau acara yang akan datang dengan Kalender Pendapatan kami.
Berapa pendapatan AZNCF untuk kuartal terakhir?
AZNCF melaporkan pendapatan sebesar $1.45 per saham untuk kuartal terakhir, lebih rendah dibandingkan dengan estimasi $1.46 per saham, yang menghasilkan kejutan -0.68%. Estimasi pendapatan untuk kuartal berikutnya adalah $1.94 per saham. Lihat lebih banyak rincian tentang pendapatan AZNCF di Profit.com.
Berapa pendapatan AZNCF untuk kuartal terakhir?
Pendapatan AZNCF untuk kuartal terakhir adalah 13.59B USD, lebih rendah dibandingkan dengan estimasi 14.57B USD. Estimasi pendapatan untuk kuartal berikutnya adalah 14.46B USD. Lihat lebih banyak statistik di laporan keuangan AZNCF di Profit.com.
Berapa Laba Bersih AZNCF untuk kuartal terakhir?
Pendapatan bersih AZNCF untuk kuartal terakhir adalah 2.99B USD, sementara kuartal sebelumnya menunjukkan 1.5B USD laba bersih yang mencatatkan perubahan 99.37%. Lihat lebih banyak statistik di laporan keuangan AZNCF di Profit.com.
¿AZNCF paga dividendos?
Sí, los dividendos de AZNCF se pagan trimestralmente. El último dividendo por acción fue 3.1. A partir de hoy, el rendimiento por dividendo (TTM)% es 2.25%.
¿Cuántos empleados tiene AZNCF?
A partir de 03 giu 2025, AZNCF emplea aproximadamente a 94300 empleados. Consulta si AZNCF está en nuestra lista de empleadores más grandes.
¿Qué es el EBITDA de AZNCF?
El EBITDA, que mide el rendimiento operativo de una empresa, refleja sus mejoras en eficiencia. El EBITDA de AZNCF es 18.28B USD, con un margen EBITDA actual de 14.14%. Consulta más estadísticas en los rapporti finanziari de AZNCF en Profit.com.
¿Cómo comprar acciones de AZNCF?
Al igual que otras acciones, las acciones de AZNCF se cotizan en bolsas de valores como PINK. La forma más fácil de comprarlas es a través de un bróker de bolsa en línea. Simplemente abre una cuenta, sigue los procedimientos del bróker y comienza a operar. Alternativamente, puedes practicar comerciando acciones de Tesla en Profit.com en torneos Playtrade o elegir un bróker recomendado para operar directamente.
¿Debería invertir en las acciones de AZNCF?
Invertir en acciones requiere una investigación exhaustiva, que incluye analizar las finanzas de la empresa, las noticias relacionadas y el análisis técnico. Actualmente, las recomendaciones de los analistas técnicos de Tesla muestran una calificación de buy.